Subsequent target validation revealed the dependence of KRAS-mutant cells on bioavailable intracellular Cu pools regulated by micropinocytosis; therefore, Cu-targeting drug molecules might have clinical potential in the context of KRAS-mutated cancers. Here, KRAS is linked to cancer.